U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Britain Courts Anthropic Amid US Defense Department Dispute 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
NEW YORK, Nov. 21, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Lannett Company, Inc. (NYSE:LCI) between September 12, 2013 and November 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of Pennsylvania. To get more information go to:
http://www.zlk.com/pslra/lannett-company
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Lannett violated securities laws by virtue of its failure to disclose that Lannett’s drug pricing relied on unsustainable pricing methodologies and that Lannett lacked effective internal controls concerning its drug pricing methodologies.
On July 16, 2014, Lannett revealed it had received interrogatories and a subpoena from the State of Connecticut Office of the Attorney General. By December 8, 2014, both the Company’s Senior Vice President of Sales and Marketing and the Company were served grand jury subpoenas. On November 4, 2016, Bloomberg reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Lannett, to determine whether they unlawfully colluded with each other to fix generic drug prices.
If you suffered a loss in Lannett you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
